a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi’s longer lasting version, Toujeo, and is likely to win a large share of the ...
Basaglar is indicated to improve glycaemic ... Sanofi is hitting back with its new insulin glargine formulation Toujeo (U300), which was filed with the European Medicines Agency in June and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results